Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that the Cocrystal management team, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 12:00 PM EST.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (cocrystalpharma.com). The video webcast replay will be made available two hours following the event.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus. Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor and Media Contact:

JTC Team, LLC
(833) 475-8247
COCP@jtcir.com

###

Staff

Recent Posts

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized…

11 hours ago

Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to…

11 hours ago

MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment

SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals…

11 hours ago

RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air

LAS VEGAS, Jan. 10, 2025 /PRNewswire/ -- RingConn, a leading smart wearable brand, is proud…

11 hours ago

1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report and Announces Management Changes

VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / 1933 Industries Inc. (the "Company" or…

11 hours ago